Con­gres­sion­al watch­dog ad­vis­es HHS to im­ple­ment 'post-mar­ket­ing' in­cen­tives to ad­dress dwin­dling an­tibi­ot­ic de­vel­op­ment ef­forts

With the Covid-19 cri­sis ex­pect­ed to shore up an­tibi­ot­ic use with op­por­tunis­tic sec­ondary bac­te­r­i­al in­fec­tions — and po­ten­tial­ly ex­ac­er­bate the rate an­tibi­ot­ic re­sis­tance — a con­gres­sion­al watch­dog has put to­geth­er a list of rec­om­men­da­tions to sort out the chal­lenges af­fect­ing an­tibi­ot­ic stew­ard­ship, track rates of drug re­sis­tance, and fix the ‘bro­ken’ mar­ket for an­tibi­otics.

While bac­te­r­i­al pathogens mu­tate and grow re­sis­tant to the ex­ist­ing crop of an­tibi­otics, dri­ven by un­bri­dled use in hu­mans and live­stock — the in­dus­try play­ers con­tribut­ing to the ar­se­nal of an­timi­cro­bials are fast dwin­dling, and the pipeline for new an­tibi­otics is em­bar­rass­ing­ly sparse, the WHO has warned.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.